Can pediatric patients receive oral ivermectin?

Can Children Take Oral Ivermectin?

Yes, children can take oral ivermectin, but it is contraindicated in those weighing less than 15 kg due to potential neurotoxicity from an immature blood-brain barrier. 1, 2

FDA-Approved Age and Weight Restrictions

• The FDA-approved ivermectin formulation (Stromectol) is not licensed for children weighing less than 15 kg because of concerns about drug penetration across an immature blood-brain barrier, which could lead to neurotoxic effects. 1, 2
• For children weighing ≥15 kg, the standard adult dose of 200 µg/kg is appropriate and safe. 1

Off-Label Use in Younger Children: Emerging Evidence

Despite the FDA contraindication, recent high-quality research demonstrates that ivermectin can be used safely in younger children under specific circumstances:

• A 2024 multicenter phase 2 trial in children aged 2–4 years (weighing 10–14 kg) treated for scabies with a 3 mg dose showed comparable drug exposure to older children receiving 200 µg/kg, with 90% achieving complete resolution and only mild adverse events in 4% of patients. 3
• A 2020 multicentric observational study of 170 infants and children weighing 4–14.5 kg (ages 1–64 months) treated with ivermectin for scabies reported adverse events in only 4% of patients, all mild and self-limiting, with no serious adverse events. 4
• A 2021 systematic review and individual patient data meta-analysis of 1,088 children weighing <15 kg found that only 1.4% experienced adverse events, all mild and self-limiting, with no serious adverse events reported. 5

Dosing for Children Under 15 kg (Off-Label)

• For children aged 3–7 months: 0.75 mg (one-quarter of a 3 mg tablet). 6
• For children aged 8–12 months: 1.5 mg (one-half of a 3 mg tablet). 6
• For children aged 13–24 months: 3 mg (one full 3 mg tablet). 6
• For children aged 2–4 years weighing 10–14 kg: 3 mg. 3

These doses are based on pharmacokinetic modeling incorporating CYP3A4 maturation and achieve median plasma exposures within 80–125% of the reference exposure in older children. 6

Critical Administration Requirements

• Ivermectin must be taken with a substantial meal (preferably high-fat) to increase bioavailability approximately 2.5-fold; taking it on an empty stomach reduces absorption by about 60%. 1, 2
• For scabies treatment, a second dose on day 14 is mandatory because ivermectin has limited ovicidal activity; omitting the second dose is the leading cause of treatment failure. 7, 1

Specific Pediatric Indications

Head Lice

• Ivermectin 200 µg/kg repeated in 10 days has been shown effective, but it should not be used in children weighing less than 15 kg due to potential neurotoxicity. 8
• Neither oral nor topical ivermectin is currently FDA-approved as a pediculicide. 8

Scabies

• Standard regimen: 200 µg/kg on day 0 and day 14, taken with food. 7, 1
• Crusted (Norwegian) scabies: Requires an intensified schedule of 200 µg/kg on days 1,2,8,9,15,22, and 29, combined with daily topical permethrin 5% cream. 1

Strongyloidiasis and Other Helminth Infections

• A single oral dose of 200 µg/kg is recommended for children older than 24 months. 1

Safety Considerations in Pediatric Populations

• No dose adjustment is required for renal impairment regardless of creatinine clearance. 7, 1
• Severe hepatic impairment: Safety of repeated dosing is uncertain; use caution or consider alternative agents. 1
• Loa loa co-infection: Children with recent travel to West or Central Africa must be screened for Loa loa; high microfilaremia (>8,000 mf/mL) can precipitate fatal encephalopathy if ivermectin is administered. 1

Common Pitfalls to Avoid

• Do not prescribe a single dose for scabies—this is the leading cause of treatment failure and may promote resistance. 7, 1
• Do not advise taking ivermectin on an empty stomach—this markedly reduces drug absorption and therapeutic efficacy. 1, 2
• Do not interpret persistent pruritus at 1 week as treatment failure—itching may persist for up to 2 weeks after successful therapy due to ongoing inflammatory response to dead mites. 7, 1
• Do not treat the child in isolation—all household and close contacts must receive the same two-dose regimen simultaneously, even if asymptomatic, to prevent reinfection. 7, 1

Post-Treatment Management

• Re-evaluate patients 2–4 weeks after the final dose to confirm cure; persistent symptoms beyond 2 weeks or detection of live mites warrants assessment for treatment failure, reinfection, or possible resistance. 7, 1
• Environmental decontamination is essential: Wash and dry all bedding and clothing on hot cycles (or dry-clean); items that cannot be laundered should be removed from body contact for at least 72 hours, as mites cannot survive off the host beyond this period. 7, 1